Exploratory delayed-start analysis of PASADENA in early-stage Parkinson's disease

The PASADENA trial (NCT03100149) evaluated the safety and efficacy of prasinezumab in early Parkinson's disease. The first part of the study did not meet the primary endpoint, change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total score (Parts I + II + III); however, differences in MDS-UPDRS Part III scores suggest less motor progression in prasinezumab-treated participants than in the placebo group. Gennaro Pagano, MD, MSc, PhD, F. Hoffmann - La Roche Ltd, Basel, Switzerland, discusses the results of an exploratory delayed-start analysis of PASADENA evaluating the efficacy of prasinezumab on motor progression and motor complications in early-stage Parkinson's disease. Participants were randomized to receive intravenous prasinezumab every four weeks for 104 weeks (early-start group, or placebo for 52 weeks, followed by prasinezumab for 52 weeks (delayed-start group, n=105). Results showed that fewer patients in the early-start group showed motor progression compared with the delayed-start group. Additionally, fewer participants in the early-start group developed motor complications compared with the delayed-start group. This interview took place at the 2022 International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.